Drop Two, Add One: Vertex Adjusts Adaptive Trial Seeking An All-Oral HCV Regimen
This article was originally published in The Pink Sheet Daily
Executive Summary
The ongoing Phase II study trying combinations backboned by telaprevir and experimental polymerase inhibitor VX-222 continues with two quad-treatment arms and a plan to drop interferon again in the first quarter.
You may also be interested in...
Will World's Largest HCV Population Have Access To Newest Treatments?
With a large patient pool and a recent expansion of government reimbursement for costly peg-interferon therapies, China is poised to see an exponential growth in its hepatitis C virus treatment market, growing north of 80% in five years, according to a recent report by research firm Decision Resources
Will World's Largest HCV Population Have Access To Newest Treatments?
Merck will work with the Chinese Physician Association on an HCV awareness campaign.
Will World's Largest HCV Population Have Access To Newest Treatments?
Merck will work with the Chinese Physician Association on an HCV awareness campaign.